Literature DB >> 32242895

Experiences and lesson strategies for cardiology from the COVID-19 outbreak in Wuhan, China, by 'on the scene' cardiologists.

Lin Zhang1, Yongzhen Fan1, Zhibing Lu1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32242895      PMCID: PMC7529146          DOI: 10.1093/eurheartj/ehaa266

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


× No keyword cloud information.

Brief overview of COVID-19 in Wuhan, China

COVID-19 has become a global health crisis since its initial outbreak in Wuhan, China in December 2019, now affecting >520 000 people worldwide. Across China, a total of 82 078 confirmed cases had been reported as of 27 March 2020, more than half of whom were from Wuhan (50 006 confirmed cases). As revealed by China CDC1 (data from 11 February 2020), the epidemic curve of onset of symptoms peaked on 23–26 January for the general population. The basic reproductive number (R0) is estimated to be 2.0–4.0. It is noteworthy that the epidemic doubling time was 2.4 days between 20 January and 2 February,2 and the growth rate had considerably slowed down thanks to the rigorous quarantine and prevention measures issued by the government. Unfortunately, 1716 health workers became infected, 63% of whom were in Wuhan.1 Of these, 14.6% of confirmed cases among health workers were classified as severe or critical and 5 deaths were noted. In a previous report from our hospital3, of the 138 COVID-19 patients, 57 (41.3%) were presumed to have acquired the infection in hospital, including 17 patients (12.3%) who were already hospitalized for other reasons and 40 health workers (29%). Patient-to-patient transmission was also presumed to have occurred. Furthermore, health worker infections seemed more overwhelming in general wards than in wards specific for patients admitted with COVID-19: 77.5% for the former and 22.5% for the latter. The above data warn that cross-infection in hospital poses a serious danger for both health workers and inpatients. Poor awareness of personal protection at the early stage of the COVID-19 outbreak may partly explain the high incidence of infection of health workers in general wards. A Department of Cardiology may also encounter COVID-19 cases in clinical practice. Large pitfalls can exist when patients are asymptomatic on admission but presented due to cardiovascular symptoms. As such, early identification and proper protection measures are crucial to reduce possible transmission among health workers and inpatients. Herein, we present the COVID-19 cases we have confronted in the department of Cardiology of Zhongnan Hospital, Wuhan University and share our experiences in containing the spread of COVID-19 in hospital.

Presentation of five COVID-19 cases in cardiology

Between 1 and 31 January 2020, of 417 inpatients and 116 health workers in our department, 4 patients (1 male, 3 female) and 1 nurse (female) were diagnosed with COVID-19. The 77-year-old male patient, who was initially admitted for acute myocardial infarction (AMI), was confirmed as COVID-19 (presumed to be hospital acquired) and died of respiratory and circulation failure 2 weeks later. In the other three patients, the outbreak occurred shortly after hospitalization but they showed no COVID-19-related symptoms, and were presumed to be already in the incubation period before admission. They eventually recovered and were discharged. The nurse probably became infected due to close contact with confirmed patients when providing nursing care under insufficient personal protection, since she had no other known exposure history. Details of these cases are given in .

Practical strategies and suggestions against COVID-19 from cardiology

To contain possible transmissions in the cardiology ward, we have elaborated a detailed protection plan defining personal protection in different clinical settings on the basis of general control and prevention principles. Our major control and prevention measures are summarized in Table . Regarding the use of personal protection equipment (PPE), facial and eye protection, gown, and gloves are considered crucial since the main transmission routes of COVID-19 are respiratory droplets and contact. The PPE is classified into three levels according to exposure risk. For instance, a level-1 PPE is used for general medical contact with non-infected inpatients in cardiology, while a level-3 PPE is proposed when aerosol-generating procedures (i.e. cardiopulmonary resuscitation) or emergent cardiovascular interventions are performed for confirmed or highly suspected cases. Practical protection and prevention measures developed in cardiology Staff and patient education Management of visitors Review infection prevention policies and procedures Pre-training of wearing protection clothing Environmental cleaning and hand hygiene Terminating the use of air conditioning and keep windows open for ventilation Division of the ward area into contaminated, transition, and clean regions to reduce cross-infection under the guidance of experts for infectious disease For suspected or confirmed patients with COVID-19 in our department before transfer to designated isolation wards of the hospital, the following measures are defined: Single-patient room equipped with air sanitizer, limit the range of patient activities, environmental cleaning and disinfection twice per day, contact precautions, designated medical team for patient management, external visits forbidden, patient required to wear mask, immediate transfer to COVID-19-specific wards once confirmed, disinfection, and disposal of patient items For patients excluded from infection: mask wearing, external visits forbidden Level 1 protection Equipment: surgical mask (or N95 respirator), disposable cap, disposable isolation gown (or white coat), medical gloves (if necessary), rapid hand disinfection solution Applied settings: clean or transition region of the workplace; general medical contact with non-infected patients Level 2 protection Equipment: disposable cap, goggles (or facemask), N95 respirator, disposable protective overall, medical gloves, disposable shoe covers, rapid hand disinfection solution Applied settings: general medical contact (not aerosol-generating procedures) with confirmed, suspected patients, or their close contacts, and patients with fever of undetermined origin Level 3 protection Equipment: disposable cap, particulate respirator (or comprehensive respiratory apparatus), N95 respirator, disposable protective overall, medical gloves (two layers), disposable shoe covers (or protective boots), disposable waterproof isolation gown, rapid hand disinfection solution Applied settings: aerosol-generating procedures (endotracheal intubation, nebulizer treatment, sputum induction, cardiopulmonary resuscitation, etc.), cardiovascular interventions (emergent coronary intervention, implantation of pacemakers or other assisting devices, etc.). PPE, personal protection equipment. Our measures are adapted from Regulation for Prevention and Control of Healthcare Associated Infection of Airborne Transmission Disease in Healthcare Facilities (People’s Republic of China, WS/T 511-2016). AMI is one of the most life-threatening cardiovascular emergencies. In response to the epidemic, a modified workflow for managing AMI patients was developed in our centre (Figure ), which had undergone repeated discussions among local cardiologists before its implementation, by fully weighing the risk–benefit ratio from both the patients’ and health workers’ perspective. Workflow for the management of STEMI patients in the context of a COVID-19 outbreak. STEMI, ST-segment elevation myocardial infarction; CCU, coronary care unit; PCI, percutaneous coronary intervention. Although primary percutaneous coronary intervention (PCI) or emergent PCI is an effective reperfusion strategy, especially for ST-segment elevation myocardial infarction (STEMI) cases, its role had to be relatively secondary in the context of the sudden COVID-19 outbreak. Increased exposure risks due to lack of negative pressure catheterization rooms and shortage of PPE and the significant increased difficulty in fine manipulation of guidewires under level-3 protection may all contribute to clinical decision-making. We recommend that fibrinolysis be preferred when both PCI and fibrinolysis can be selected. Once PCI is required, all staff engaged should be under level-3 protection, and thorough environmental disinfection must be given after each PCI. Similarly, for patients with non-STEMI, PCI can be performed in the high-risk population group: ongoing ischaemic symptoms, haemodynamic instability, and malignant arrhythmias. An in-hospital multidisciplinary consultation (involving experts from cardiology, ICU, department of infectious disease, and emergency department) should be organized in cases of AMI or other cardiovascular emergencies complicated with COVID-19. However, we have to acknowledge that our changed treatment for AMI is not evidence based but is a compromise in the context of the COVID-19 pandemic. Further validations may be warranted to observe its potential impact on patient outcome.

Conclusion

Great care should also be taken by cardiologists since they may also confront COVID-19 cases. Prompt identification could be challenging when the patients are asymptomatic or still in an incubation period at admission, highlighting the importance of early proper protection measures in advance. Our practical strategies could be useful for cardiology departments worldwide in response to the COVID-19 outbreak.

References

References are available as Supplementary material at European HeartJournal online. Click here for additional data file.
Table 1

Practical protection and prevention measures developed in cardiology

Key measures

Staff and patient education

Management of visitors

Review infection prevention policies and procedures

Pre-training of wearing protection clothing

Environmental cleaning and hand hygiene

Terminating the use of air conditioning and keep windows open for ventilation

Division of the ward area into contaminated, transition, and clean regions to reduce cross-infection under the guidance of experts for infectious disease

For suspected or confirmed patients with COVID-19 in our department before transfer to designated isolation wards of the hospital, the following measures are defined:

Single-patient room equipped with air sanitizer, limit the range of patient activities, environmental cleaning and disinfection twice per day, contact precautions, designated medical team for patient management, external visits forbidden, patient required to wear mask, immediate transfer to COVID-19-specific wards once confirmed, disinfection, and disposal of patient items

For patients excluded from infection: mask wearing, external visits forbidden

PPE applied

Level 1 protection

Equipment: surgical mask (or N95 respirator), disposable cap, disposable isolation gown (or white coat), medical gloves (if necessary), rapid hand disinfection solution

Applied settings: clean or transition region of the workplace; general medical contact with non-infected patients

Level 2 protection

Equipment: disposable cap, goggles (or facemask), N95 respirator, disposable protective overall, medical gloves, disposable shoe covers, rapid hand disinfection solution

Applied settings: general medical contact (not aerosol-generating procedures) with confirmed, suspected patients, or their close contacts, and patients with fever of undetermined origin

Level 3 protection

Equipment: disposable cap, particulate respirator (or comprehensive respiratory apparatus), N95 respirator, disposable protective overall, medical gloves (two layers), disposable shoe covers (or protective boots), disposable waterproof isolation gown, rapid hand disinfection solution

Applied settings: aerosol-generating procedures (endotracheal intubation, nebulizer treatment, sputum induction, cardiopulmonary resuscitation, etc.), cardiovascular interventions (emergent coronary intervention, implantation of pacemakers or other assisting devices, etc.).

PPE, personal protection equipment.

Our measures are adapted from Regulation for Prevention and Control of Healthcare Associated Infection of Airborne Transmission Disease in Healthcare Facilities (People’s Republic of China, WS/T 511-2016).

  12 in total

1.  Prevention and Treatment Strategies for the Cardiology Department of a Non-COVID-19 Designated Hospital in the Post-Epidemic Period.

Authors:  Qian Fan; Xin Chen; Yan Lin; Zhiquan Wang
Journal:  Risk Manag Healthc Policy       Date:  2020-07-31

Review 2.  Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement.

Authors:  Daniel Lenihan; Joseph Carver; Charles Porter; Jennifer E Liu; Susan Dent; Paaladinesh Thavendiranathan; Joshua D Mitchell; Anju Nohria; Michael G Fradley; Iskra Pusic; Keith Stockerl-Goldstein; Anne Blaes; Alexander R Lyon; Sarju Ganatra; Teresa López-Fernández; Rupal O'Quinn; Giorgio Minotti; Sebastian Szmit; Daniela Cardinale; Jose Alvarez-Cardona; Giuseppe Curigliano; Tomas G Neilan; Joerg Herrmann
Journal:  CA Cancer J Clin       Date:  2020-09-10       Impact factor: 508.702

Review 3.  Management and Treatment of COVID-19: The Chinese Experience.

Authors:  Fujun Peng; Lei Tu; Yongshi Yang; Peng Hu; Runsheng Wang; Qinyong Hu; Feng Cao; Taijiao Jiang; Jinlyu Sun; Guogang Xu; Christopher Chang
Journal:  Can J Cardiol       Date:  2020-04-17       Impact factor: 5.223

4.  Compromised STEMI reperfusion strategy in the era of COVID-19 pandemic: pros and cons.

Authors:  Lin Zhang; Yongzhen Fan; Zhibing Lu
Journal:  Eur Heart J       Date:  2020-11-07       Impact factor: 29.983

Review 5.  COVID-19 and Acute Coronary Syndromes: Current Data and Future Implications.

Authors:  Matteo Cameli; Maria Concetta Pastore; Giulia Elena Mandoli; Flavio D'Ascenzi; Marta Focardi; Giulia Biagioni; Paolo Cameli; Giuseppe Patti; Federico Franchi; Sergio Mondillo; Serafina Valente
Journal:  Front Cardiovasc Med       Date:  2021-01-28

6.  Cardiac Surgery in the Time of Coronavirus.

Authors:  Mauro Del; Gabriele Tamagnini
Journal:  Braz J Cardiovasc Surg       Date:  2020-06-01

7.  Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic.

Authors:  Nan Wang; Min Zhang; Huajun Su; Zhonglue Huang; Yongbo Lin; Min Zhang
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

8.  STEMI in COVID-19 patients: thrombolysis-first approach could yield more risk than benefit.

Authors:  Dimitrios A Vrachatis; Spyridon Deftereos; Giulio G Stefanini
Journal:  Eur Heart J       Date:  2020-11-07       Impact factor: 29.983

9.  Pulmonary embolism in COVID-19 patients: a French multicentre cohort study.

Authors:  Charles Fauvel; Orianne Weizman; Antonin Trimaille; Delphine Mika; Thibaut Pommier; Nathalie Pace; Amine Douair; Eva Barbin; Antoine Fraix; Océane Bouchot; Othmane Benmansour; Guillaume Godeau; Yasmine Mecheri; Romane Lebourdon; Cédric Yvorel; Michael Massin; Tiphaine Leblon; Chaima Chabbi; Erwan Cugney; Léa Benabou; Matthieu Aubry; Camille Chan; Ines Boufoula; Clement Barnaud; Léa Bothorel; Baptiste Duceau; Willy Sutter; Victor Waldmann; Guillaume Bonnet; Ariel Cohen; Théo Pezel
Journal:  Eur Heart J       Date:  2020-07-01       Impact factor: 29.983

10.  Concerns for management of STEMI patients in the COVID-19 era: a paradox phenomenon.

Authors:  Panayotis K Vlachakis; Anastasios Tentolouris; Ioannis Kanakakis
Journal:  J Thromb Thrombolysis       Date:  2020-11       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.